Adipokines and the Risk of Reflux Esophagitis


We aimed to risk faoctors for GERD and association between visceral obesity, plasma adipoline(leptin, adiponectin, IL-6, TNF-α)and development of reflux esophagitis in healthy Koreans.

Full Title of Study: “Adipokines and the Risk of Reflux Esophagitis : Prospective Case-control Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2013

Arms, Groups and Cohorts

  • Reflux esophagitis
    • those with endoscopically proven reflux esophagitis
  • Normal
    • those with normal GFS finding (without definite mucosal break at Z-line)

Clinical Trial Outcome Measures

Primary Measures

  • Difference in serum adipokine levels between case and control groups
    • Time Frame: 2 month lager (after sampling)

Participating in This Clinical Trial

Inclusion Criteria

  • endoscopically proven reflux esophagitis Exclusion Criteria:

  • those with esophageal hiatal hernia, current PPI medication, upper GI operation history

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Seoul National University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Donghee Kim, Clinical Assistant Professor – Seoul National University Hospital
  • Overall Contact(s)
    • Kyung-Sang Yu, Professor, +82-2-2072-1920,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.